Mesa Labs Q4 2020 Earnings Report
Key Takeaways
Mesa Labs reported a 29% increase in revenues for Q4 2020, reaching $34.208 million. However, operating income decreased by 65% to $899,000, and the company experienced a net loss of $1.680 million, or $(0.37) per diluted share. Excluding unusual items, adjusted operating income increased by 32%.
Revenues increased by 29% compared to the same quarter in the prior year, reaching $34,208,000.
Operating income decreased by 65% to $899,000 due to unusual items.
Net loss was $1,680,000, a decrease of 220% or $(0.37) per diluted share.
Sterilization and Disinfection Control division delivered strong results with 17% total and organic revenue growth.
Mesa Labs
Mesa Labs
Mesa Labs Revenue by Segment
Forward Guidance
COVID-19 is expected to continue to negatively impact sales during the remainder of the fiscal year, with varying effects on different divisions.
Positive Outlook
- Solid cash position.
- Strong financial and operational foundation.
- Flexibility in responding to pandemic challenges.
- Readiness for anticipated recovery.
- Broad exposure to biopharmaceuticals, medical devices, and healthcare services provides a solid long-term organic growth trajectory and attractive acquisition opportunities.
Challenges Ahead
- COVID-19 restrictions will continue to have a negative impact during the remainder of this fiscal year that we are unable to quantify at this time.
- Divisions serving biopharmaceutical and healthcare customers may see sales activity resume more quickly but there may be an additional lag for hardware revenues.
- Instruments division may rebound more slowly.
- Travel restrictions impacting the ability to complete Gyros Protein Technologies integration in a timely manner.
- Potential for continued negative impact from COVID-19.